Open Access Open Access  Restricted Access Subscription or Fee Access

Role of Proteomics in Diagnosis of Cancer

Prajjwal Shukla

Abstract


Proteomic technologies have emerged as an important addition to genomic and antibody-based technology for diagnosis of cancer. Important technologies include 2-D Gel Electrophoresis, Mass Spectroscopy, Laser capture microdissection, detection of molecular markers of cancer, and protein pattern proteomic technologies have a potential in developing molecular diagnostics and markers for the early detection of cancer. Proteomics is valuable in the discovery of biomarkers because the proteomes reflect both the intrinsic genetic program of the cell and impacts of its environment. However, I will say that proteomics is the most powerful tool that has emerged to study the cancer or diagnosis of cancer in early stages.


Keywords


2D-GE (2-D Gel Electrophoresis), BRCA 2 (Breast Cancer 2), BRCA 1 (Breast Cancer 1), Cancer Diagnosis, Proteomics, Molecular Diagnosis

Full Text:

PDF

References


Jain, K. K. "Role of proteomics in diagnosis of cancer." Technology in cancer research & treatment 1, no. 4 (2002): 281-286.

Breuer, E.K.Y. and Murph, M.M., 2011. The role of proteomics in the diagnosis and treatment of women's cancers: current trends in technology and future opportunities. International journal of proteomics, 2011.

Tonry, C.L., Leacy, E., Raso, C., Finn, S.P., Armstrong, J. and Pennington, S.R., 2016. The role of proteomics in biomarker development for improved patient diagnosis and clinical decision making in prostate cancer. Diagnostics, 6(3), p.27.

Wu, W., Hu, W. and Kavanagh, J.J., 2002. Proteomics in cancer research. International Journal of Gynecologic Cancer, 12(5).

Simone, N.L., Paweletz, C.P., Charboneau, L., Petricoin, E.F. and Liotta, L.A., 2000. Laser capture microdissection: beyond functional genomics to proteomics. Molecular Diagnosis, 5(4), pp.301-307.

Lüftner, D. and Possinger, K., 2002. Nuclear matrix proteins as biomarkers for breast cancer. Expert review of molecular diagnostics, 2(1), pp.23-31.

Brünagel, G., Vietmeier, B.N., Bauer, A.J., Schoen, R.E. and Getzenberg, R.H., 2002. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer research, 62(8), pp.2437-2442.

Emmert‐Buck, M.R., Gillespie, J.W., Paweletz, C.P., Ornstein, D.K., Basrur, V., Appella, E.,Wang, Q.H., Huang, J., Hu, N., Taylor, P. and Petricoin III, E.F., 2000. An approach to proteomic analysis of human tumors. Molecular Carcinogenesis: Published in cooperation with the University of Texas MD Anderson Cancer Center, 27(3), pp.158-165.

Alaiya, A.A., Franzén, B., Hagman, A., Dysvik, B., Roblick, U.J., Becker, S., Moberger, B., Auer, G. and Linder, S., 2002. Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. International journal of cancer, 98(6), pp.895-899.

Fung, E.T., Wright Jr, G.L. and Dalmasso, E.A., 2000. Proteomic strategies for biomarker identification: progress and challenges. Current opinion in molecular therapeutics,2(6),pp.643-650.




DOI: https://doi.org/10.37628/ijcbb.v7i1.718

Refbacks

  • There are currently no refbacks.